Combined Radiotherapy and Chemotherapy: Theoretical Considerations and Biological Premises

  • Branislav Jeremic
  • Dusan Milanovic
  • Nenad Filipovic
Part of the Medical Radiology book series (MEDRAD)


Starting point for full realization of clinical achievements of combined radiation therapy and chemotherapy in lung cancer is nothing but full understanding of general theoretical consideration as well as basic radiobiological premises of combined radiation and chemotherapy. Both are nowadays considered as mandatory ingredients in any consideration of combined radiation therapy and chemotherapy in lung cancer, as well as cancers in other tumour sites. More than 30 years ago, four basic mechanisms through which radiation therapy and chemotherapy can interact were established including spatial cooperation, independent cell kill, protection of normal tissues and enhancement of tumor response, the latter frequently replaced by terms such as radiosensitization or radio enhancement. Clinical evidence supports importance of exploitable mechanisms, although protection of normal tissue has never been proven. Novel radiation therapy technologies, occasionally changing fractionation pattern and new drugs/compounds will set the stage and scene for further verification of basic principles of combined radiation therapy and chemotherapy in clinical research of lung cancer.


Induction Chemotherapy Radiation Therapy Oncology Group Consolidation Chemotherapy Combine Radiation Therapy Intrathoracic Tumour 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Akerley W, Herndon JE Jr, Lyss AP, Choy H, Turrisi A, Graziano S, Williams T, Zhang C, Vokes EE, Green MR (2005) Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study–CALGB 9534. Clin Lung Cancer 7:47–53PubMedCrossRefGoogle Scholar
  2. Belani CP, Wang W, Johnson DH (2005) Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 23:3760–3767PubMedCrossRefGoogle Scholar
  3. Brown JM (2001) Therapeutic targets in radiotherapy. Int J Radiat Oncol Biol Phys 49:319–326PubMedCrossRefGoogle Scholar
  4. Byhardt RW, Scott CB, Ettinger DS (1995) Concurrent hyperfractionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer. Results of Radiation Therapy Oncology Group 90-15. Cancer 75:2337–2344PubMedCrossRefGoogle Scholar
  5. Byhardt RW, Scott C, Sause WT (1998) Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 42:469–478PubMedCrossRefGoogle Scholar
  6. Chen Y, Pandya K, Keng PC, Johnstone D, Li J, Lee Y-J (2003) Phase I/II clinical study of pulsed paclitaxel radiosensitization for thoracic malignancy: a therapeutic approach on the basis of preclinical research of human cancer cell lines. Clin Cancer Res 9:969–975PubMedGoogle Scholar
  7. Choy H, Akerley W, Safran H et al (1998) Multiinstitutional phase II trial of paclitaxel, carboplatin and concurrent radiation therapy for locally advanced nonsmall cell lung cancer. J Clin Oncol 16:3316–3322PubMedGoogle Scholar
  8. Choy H, Devore RW 3rd, Hande KR et al (2000) A phase II study of paclitaxel, carboplatin and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network study). Int J Radiat Oncol Biol Phys 47:931–937PubMedCrossRefGoogle Scholar
  9. Clamon G, Herndon J, Cooper R (1999) Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia group B and the Eastern Cooperative Oncology Group. J Clin Oncol 17:4–11PubMedGoogle Scholar
  10. Curran WJ Jr, Scott C, Langer C, Komaki R, Lee JS, Hauser S (2000) Phase III comparison of sequential Vs cancer (NSCLC): initial report of Radiation Therapy Oncology Group concurrent chemoradiation for patients with unresected stage III non-small cell lung (RTOG). Proc Am Soc Clin Oncol 19:484a (Abstract 1891)Google Scholar
  11. Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC (1990) A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323:940–945PubMedCrossRefGoogle Scholar
  12. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692–2699PubMedGoogle Scholar
  13. Furuse K, Hosoe S, Masuda N, Sugiura S, Yokota K, Ohbayashi M (2000) Impact of tumor control on survival in unresectable stage III non-small cell lung cancer (NSCLC) treated with concurrent thoracic radiotherapy (TRT) and chemotherapy (CT). Proc Am Soc Clin Oncol 19:484a (Abstract 1893)Google Scholar
  14. Gandara DR, Chansky K, Albain KS et al (2006) Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group study (S9504). Clin Lung Cancer 8:116–121PubMedCrossRefGoogle Scholar
  15. Hanna N, Neubauer M, Yiannoutsos C, McGarry R, Arseneau J, Ansari R, Reynolds C, Govindan R, Melnyk A, Fisher W, Richards D, Bruetman D, Anderson T, Chowhan N, Nattam S, Mantravadi P, Johnson C, Breen T, White A, Einhorn L, Hoosier Oncology Group; US Oncology (2008) Phase III study of cisplatin, etoposide and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 26:5755–5760PubMedCrossRefGoogle Scholar
  16. Huang SM, Harari PM (1999) Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 17:259–269PubMedCrossRefGoogle Scholar
  17. Jeremic B, Shibamoto Y, Acimovic L, Djuric L (1995) Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 13:452–458PubMedGoogle Scholar
  18. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S (1996) Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non small cell lung cancer: a randomized study. J Clin Oncol 14:1065–1070PubMedGoogle Scholar
  19. Kishi K, Petersen S, Petersen C, Hunter N, Mason K, Masferrer JL (2000) Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 60:1326–1331PubMedGoogle Scholar
  20. Komaki R, Scott C, Ettinger D et al (1997) Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92–04. Int J Radiat Oncol Biol Phys 38:149–155PubMedCrossRefGoogle Scholar
  21. Lau D, Leigh B, Gandara D, Edelman M, Morgan R, Israel V (2001) Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial. J Clin Oncol 19:42–447Google Scholar
  22. Le Chevalier T, Arriagada R, Tarayre M, Lacombe-Terrier MJ, Laplanche A, Quoix W (1992) Significant effect of adjuvant chemotherapy on survival in locally advanced non small cell lung carcinoma. J Natl Cancer Inst 84:58 (letter)PubMedCrossRefGoogle Scholar
  23. Lee JS, Scott C, Komaki R et al (1996) Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer Radiation Therapy Oncology Group protocol 91–06. J Clin Oncol 14:1055–1064PubMedGoogle Scholar
  24. Milas L (2001) Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. Semin Radiat Oncol 11:290–299PubMedCrossRefGoogle Scholar
  25. Qiao WB, Zhao YB, Zhao YH, Wang RZ (2005) Clinical and dosimetric factors of radiation induced esophageal injury: radiation-induced esophageal toxicity. World J Gastroenterol 11:2626–2629PubMedGoogle Scholar
  26. Raju U, Nakata E, Yang P, Newman RA, Ang KK, Milas L (2002) In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations. Int J Radiat Oncol Biol Phys 54:886–894PubMedCrossRefGoogle Scholar
  27. Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R (1995) Radiation Therapy Oncology Group 88–08 and Eastern Cooperative Oncology Group 4588: preliminary results of a phase III trial in regionally advanced, unresectable nonsmall cell lung cancer. J Natl Cancer Inst 87:198–205PubMedCrossRefGoogle Scholar
  28. Schaake-Koning C, van der Bogaert W, Dalesio O, Festen J, Hoogenhout J, van Houtte P (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 326:524–530PubMedCrossRefGoogle Scholar
  29. Sekine I, Nokihara H, Sumi M, Saijo N, Nishiwaki Y, Ishikura S, Mori K, Tsukiyama I, Tamura T (2006) Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer. J Thorac Oncol 1:810–815PubMedCrossRefGoogle Scholar
  30. Socinski MA, Blackstock AW, Bogart JA, Wang X, Munley M, Rosenman J, Gu L, Masters GA, Ungaro P, Sleeper A, Green M, Miller AA, Vokes EE (2008) Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 26:2457–2463PubMedCrossRefGoogle Scholar
  31. Steel GG, Peckham MJ (1979) Exploitable mechanisms in combined radiotherapy and chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5:85–91PubMedCrossRefGoogle Scholar
  32. Vokes EE, Herndon JE 2nd, Crawford J, Leopold KA, Perry MC, Miller AA, Green MR (2002) Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non small-cell lung cancer: Cancer and Leukemia Group B study 9431. J Clin Oncol 20:4191–4198PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg  2011

Authors and Affiliations

  • Branislav Jeremic
    • 1
  • Dusan Milanovic
    • 2
  • Nenad Filipovic
    • 3
  1. 1.Institute of Lung DiseasesSremska KamenicaSerbia
  2. 2.Department of Radiation OncologyUniversity of FreiburgFreiburgGermany
  3. 3.Bioengineering Research CentreKragujevacSerbia

Personalised recommendations